Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Med12 and p300 chips in HSPCs

ABSTRACT: We characterized the genome wide occupancy of Med12 and p300 in mouse HSPCs. We also characterize p300 occupancy upon shRNA against control or Med12.

ORGANISM(S): Mus musculus

PROVIDER: GSE76053 | GEO | 2016/08/25

SECONDARY ACCESSION(S): PRJNA306094

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Med12 and p300 chips in HSPCs

Project description:We characterized the genome wide occupancy of Med12 and p300 in mouse HSPCs. We also characterize p300 occupancy upon shRNA against control or Med12. ChIP-seq analysis of Med12 and/or p300 in untreated HSPCs

2016-08-25 | E-GEOD-76053 | biostudies-arrayexpress

Histone chromatin modifications in control and Med12-deficient mouse HSPCs

Project description:Using iChIP, we map H3K27Ac, H3K4me3 and H3K4me1 in small populations (HSPCs) in the presence or absence of Med12 and identify affected super-enhancers. iChIP was performed using previously published protocols (Lara-Astiaso et al, 2014 Immunogenetics. Chromatin state dynamics during blood formation - Science, 345, 6199) Examination of histone modification in mouse HSPCs with and without Med12

2016-08-25 | E-GEOD-76052 | biostudies-arrayexpress

Histone chromatin modifications in control and Med12-deficient mouse HSPCs

2016-08-25 | GSE76052 | GEO

Mus musculus

Project description:Med12 and p300 chips in HSPCs

| PRJNA306094 | ENA

CDK8 and MED12 knockdown in R1 mouse ES cells

2012-03-05 | GSE30816 | GEO

CDK8 and MED12 knockdown in R1 mouse ES cells

Project description:Transcriptional profiling of R1 mouse ES cells infected with non-targeting control (NTC) shRNA and two different shRNA sequences against Cdk8 (shCdk8-1 and shCdk-2) and Med12 (shMed12-1 and shMed12-2). Multi-condition experiment comparing shNTC versus shCdk8-1 and shCdk8-2 after 8 days (3 biological replicates each) and shNTC versus shCdk8-1, shCdk8-2, shMed12-1, and shMed12-2 after 13 days (3 biological replicates each); in total 24 samples profiled.

2012-03-05 | E-GEOD-30816 | biostudies-arrayexpress

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [DIP-seq]

Project description:The p300 lysine acetyltransferase (KAT) can function as an oncogene or a tumor suppressor in hematologic malignancies. We have identified a tumor suppressor role for p300 in myelodysplastic syndrome (MDS) driven by Tet2 deficiency. Compared to Tet2-null hematopoietic stem and progenitor cells (HSPCs), HSPCs lacking both p300 and Tet2 (double knock out, DKO) displayed enhanced proliferation and impaired differentiation. Consequently, p300Δ/Δ Tet2-/- mice developed acute myeloid leukemia. p300 loss in Tet2-/- HSPCs induced a global epigenomic reprogramming that enhanced leukemogenicity at least in part by increasing expression of Myb, as knock-down of Myb specifically hindered the proliferation of the DKO HSPCs. We show that p300 KAT activity regulates the function of Tet2 null HSPCs, and that augmenting p300 function impairs their unlimited self-renewal. Such a strategy could prove useful in individuals with Tet2 deficient hematopoiesis or MDS.

2021-11-03 | GSE145877 | GEO

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ChIP-seq]

2021-11-03 | GSE145876 | GEO

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [ATAC-Seq]

2021-11-03 | GSE145875 | GEO

p300 suppresses the transition of myelodysplastic syndrome to acute myeloid leukemia [RNA-Seq]

2021-11-03 | GSE145819 | GEO